Sarepta Therapeutics, Inc. — 2013 Q1 Form 10-Q Summary
Business context and reporting period
Sarepta is a development-stage biopharmaceutical company focused on RNA-based therapeutics for rare and infectious diseases. Its lead programs were eteplirsen for Duchenne muscular dystrophy and AVI-7288 for Marburg virus. The filing covers the three months ended March 31, 2013. Unless stated otherwise, amounts are in thousands.
Financial performance and condition
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Revenue | $4,474 | $11,212 | Down 60% |
| Research and development expense | $13,762 | $14,805 | Down 7% |
| General and administrative expense | $6,127 | $3,281 | Up 87% |
| Operating loss | $(15,415) | $(6,874) | Loss increased 124% |
| Net loss | $(42,084) | $(17,704) | Loss increased 138% |
| Basic and diluted loss per share | $(1.32) | $(0.78) | Worsened |
| Net cash used in operating activities | $(14,993) | $(9,049) | Higher use of cash |
- Approximate operating margin was negative 344%, compared with negative 61% in Q1 2012; approximate net margin was negative 941%, compared with negative 158%.
- Revenue consisted primarily of government research contracts: $2,614 from the July 2010 Marburg/Ebola contract, $1,806 from the August 2012 intramuscular Marburg contract, and $54 from the European Commission DMD agreement.
- Cash and cash equivalents were $167.9 million at March 31, 2013, down from $187.7 million at December 31, 2012. The company stated that available cash was sufficient to fund operations for at least the next twelve months.
- The company purchased $7.25 million of restricted investments to secure letters of credit for manufacturing agreements. Total assets were $193.3 million and shareholders’ equity was $87.3 million.
- Debt was $1.735 million, consisting of $90 thousand current debt and $1.645 million long-term debt. The company reported no material off-balance-sheet arrangements.
- Current liabilities included a $91.1 million warrant liability, up from $65.2 million at year-end 2012. This was a non-cash liability, but its $26.9 million increase was recorded as a loss and materially increased the quarterly net loss.
- Contractual obligations totaled $43.9 million, including $28.99 million of purchase obligations, $13.14 million of operating leases, and $1.735 million of long-term debt.
Material changes versus the prior comparable period
- Revenue fell $6.7 million, primarily because the Ebola portion of the DoD contract was stopped and terminated in 2012 and Marburg-related activity declined. The decrease was partly offset by the new intramuscular Marburg contract.
- Research and development expense declined $1.0 million as Ebola and Marburg contract costs decreased, partly offset by higher personnel, proprietary research, and intramuscular contract costs.
- General and administrative expense increased $2.8 million, driven mainly by higher personnel costs, stock-based compensation, and professional services.
- Net loss increased $24.4 million, primarily from the $8.5 million increase in operating loss and the $16.0 million higher non-cash warrant valuation loss.
- Operating cash use increased $5.9 million, while investing cash use increased because of the $7.3 million restricted investment purchase.
- In January 2013, the company sold approximately 87,000 shares under its ATM offering for $2.1 million in net proceeds, exhausting the remaining capacity under that agreement. Warrant and option exercises provided additional proceeds.
- The company recorded $462 thousand of restructuring charges related to its headquarters relocation; $446 thousand remained accrued at March 31, 2013.
Guidance, outlook, commentary, risks, and unusual items
- Management expected to complete planning for a pivotal eteplirsen trial by the end of 2013 and begin dosing in early 2014, subject to regulatory and clinical developments.
- The company reported that the FDA requested additional information regarding the eteplirsen dataset to assess whether it could support an accelerated-approval NDA filing. The timing and regulatory pathway remained uncertain.
- The Marburg contract’s later segments could provide approximately $84.4 million of additional funding if the DoD exercises its options. These options are not assured.
- Government funding is subject to appropriations, continuing-resolution constraints, sequestration, and the government’s right to terminate contracts for convenience. The company had already experienced termination of the Ebola program due to funding constraints.
- The company had no material product-sales revenue and expected to continue incurring operating losses. It anticipated seeking additional financing through equity, debt, government contracts, collaborations, or licensing transactions.
- Key risks include clinical-trial failure or delay, inability to obtain regulatory approval, manufacturing scale-up and third-party supplier dependence, intellectual-property disputes, competition, dilution from future equity issuance, and dependence on government contracts.
- The April 10, 2013 amended UWA license agreement could require up to $7.1 million in upfront and development milestone payments, plus low-single-digit royalties on product sales.
- Management stated that disclosure controls and procedures were effective as of March 31, 2013, with no material changes to internal control over financial reporting.
Important facts for investors to verify
- Progress, regulatory feedback, and filing strategy for eteplirsen, including the prospects for accelerated approval and the timing of a pivotal trial.
- DoD funding, option exercises, and remaining scope of the Marburg contracts amid sequestration and appropriations risk.
- Cash runway after planned DMD development, manufacturing scale-up, contractual obligations, and potential additional financing.
- Future changes in the fair value of the warrant liability and its effect on reported earnings, despite being non-cash.
- Manufacturing capacity, vendor commitments secured by the $7.3 million letters of credit, and the ability to supply later-stage clinical trials.
- Potential patent claims affecting eteplirsen, including the identified Prosensa-related European intellectual-property risk.